Mok Oh

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

Kohei Shitara, Florian Lordick, Yung‐Jue Bang et al. · The Lancet · 2023 · 609 citations

Oncology, Esophageal Cancer, Gastrointestinal Oncology +9

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial

Manish A. Shah, Kohei Shitara, Jaffer A. Ajani et al. · Nature Medicine · 2023 · 450 citations · Full text

Esophageal Cancer, Glow Trial, Cancer Management +16

Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma

Abdulaali R. Almutairi, Nimer S. Alkhatib, Mok Oh et al. · JAMA Dermatology · 2018 · 35 citations · Full text

Sensorineural hearing loss with macrolide antibiotics exposure: a meta-analysis of the association

Yazed Saleh Alsowaida, Abdulaziz Almulhim, Mok Oh et al. · International Journal of Pharmacy Practice · 2020 · 19 citations

Management of nausea and vomiting (N/V) following first-line (1L) zolbetuximab + chemotherapy treatment in claudin-18.2 (CLDN18.2)+, HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Analysis from the phase 3 SPOTLIGHT and GLOW studies.

Kohei Shitara, Rupesh Pophale, Maria Matsangou et al. · Journal of Clinical Oncology · 2024 · 15 citations